Credit: Pixabay/CC0 Public Domain
Sotagliflozin, Drug Recently Approved by the Food and Drug Administration to Treat Type 2 Diabetes and Kidney Disease with Addijascular Cardiovascular Risk Factors, Can Significantly Reduce Heart Attack and Stroke Among These Pats Research.
Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of Two Proteins, Known As SGLT1 and SGLT2, Which Move Glucose and Sodium Across Cell Membranes and Help Control Blood Sugar Levels. OHER SGLT2 INHIBITORS OF NOT AS SIGNENTLY BLOCK SGLT1.
The Study, published in The Lancet Diabetes & Endocrinology, is the first to show that an sglt inhibitor hasse unique cardiovascular benefits. The Results Mean That Sotagliflozin Could Become More Widely Used to Reduce the Risk of Deadly Cardiovascular Events Glory.
“These Results demonstrate the new mechanism of action –combined blockade with sotagliflozin of the sglt1 receptors (Found in the Kidney, Gut, Heart, and Brain) and Sglt2 recetors (Found in the Kidney) – Tto Reduce Heart Attack and Stroke Risk,” SAYS STUDY CHAIR DEEPAK L. BHET, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai.
“The Benefits Seen here are distinct from those seen with the other popular Sglt2 Inhibitors in Widespread Clinical Use for Diabetes, Heart Failure, and Kidney Disease.”
The Randomized, Multicenter Trial, Known as Scored, Analyzed the Ability of Sotagliflozin to Reduce the Risks of Life-Threatning Cardiovascular Outcomes.
Researchers Enrolled 10,584 Patients with Chronic Kidney Disease, Type 2 Diabetes, and AddiTeal Cardiovascular Risk Factors; RANDOMLY ASSIGNED THEM TO SOTAGLIFLOZIN OR PLACEBO; and followed them for an averag of 16 months.
Patients in the Sotagliflozin Group Had A 23% Reduction in the Rate of Heart Attacks, Strokes, and Deaths From Such Cardiovascular Causes Compreded with the placebo group.
“Physicians Now Have a New Option to Reduce Global Cardiovascular Risk Such As Heart Failure, Progression of Kidney Disease, Heart Attack, and Stroke in Patients with Eight Heart Failure or Type 2 Diabetes, Chronic Kidney Disease, and other cardiovascular risk factors,” ADDS ” Dr. Bhatt.
“This Drug Was Approved to Reduce the Risk of Deaths From Cardiovascular Causes, Hospitalizations for Heart Failure, and Urgent Heart Failure Visits for Patients with Either Heart Failure or Type 2 Diabetes, Chronic Kidney Disease, and Other Cardiovascular Risk Factors. Data Show that it addiTionally reduces the risk of Heart Attacks and Strokes, and We Could See More Widespread Use A Result. “
More information:
Effect of Sotagliflozin on Major Adverse Cardiovascular Events: A Prespecified Secondary Analysis of the Scored Randomized Trial, The Lancet (2025).
Citation: Research Shows Sotagliflozin is the First Medication of Its Kind to Significantly Reduce Both Heart Attacks and Strokes (2025, February 14) Retrieved 14 February 2025 from
This document is Subject to Copyright. Apart from Any Fair Dealing for the Purpose of Private Study or Research at Part May Be Reproduced Without The Written Permission. The Content is Provided for Information Purposes Only.
